Exelixis Q2 adjusted EPS beats expectations

Exelixis

28/07/2025 21:12

Overview

Exelixis Q2 2025 revenue misses analyst expectations, adjusted EPS beats, per LSEG data

Net product revenues rose due to higher sales volume of cabozantinib franchise

Co reports positive results from STELLAR-303 trial in colorectal cancer

Outlook

Exelixis maintains 2025 revenue guidance at $2.25 bln - $2.35 bln

Company expects 2025 net product revenues of $2.05 bln - $2.15 bln

Exelixis anticipates 2025 R&D expenses of $925 mln - $975 mln

Company plans to announce new zanzalintinib trials soon

Result Drivers

CABOMETYX LAUNCH - Successful U.S. launch for advanced neuroendocrine tumors, capturing leading share of new patient starts

HIGHER SALES VOLUME - Increase in net product revenues driven by higher sales volume of cabozantinib franchise

STELLAR-303 RESULTS - Positive topline results in colorectal cancer, plans to seek regulatory approval

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$568.30 mln
$574.50 mln (19 Analysts)
Q2 Adjusted EPS
Beat
$0.75
$0.56 (16 Analysts)
Q2 Adjusted Net Income
Beat
$212.60 mln
$158.30 mln (15 Analysts)
Q2 Net Income
$184.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Exelixis Inc is $46.00, about 0.9% above its July 25 closing price of $45.60

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nBw3gkCtYa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)